# Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

> **NCT04726332** · PHASE1 · TERMINATED · sponsor: **Exelixis** · enrollment: 52 (actual)

## Conditions studied

- Neoplasm Malignant
- Epithelial Ovarian Cancer
- Triple Negative Breast Cancer
- Hormone Receptor Positive Breast Carcinoma
- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** XL102
- **DRUG:** Fulvestrant
- **DRUG:** Abiraterone
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT04726332
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-10
- **Primary completion:** 2024-05-02
- **Final completion:** 2024-05-02
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2024-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04726332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04726332, "Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04726332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*